- Details
- Ana Aparicio discusses her work with aggressive variant prostate cancer and her group’s research using immunohistochemistry results and genomic analysis to identify patients with a specific molecular signature. The research concludes that this molecular signature appears to identify the people that benefit from the addition of carboplatin to cabazitaxel chemotherapy. People that have the signature...
|
- Details
- Matt Rettig discusses POPCaP and his work involving the health of veterans with prostate cancer and ongoing clinical trials going on exclusively within the Veterans Health Administration (VA) system. The Precision Oncology Program for Cancer of the Prostate (POPCaP), a partnership between the VA and the Prostate Cancer Foundation (PCF) to create a system of excellence for prostate cancer in VA is...
|
- Details
- Maria de Santis and Chuck Ryan share a conversation on the rapidly changing landscape for the treatment of locally advanced prostate cancer. A focus of the discussion centers around the STAMPEDE data demonstrating benefit with the early use of abiraterone and the use of radiation. They also discuss the role of docetaxel in this evolving environment based on data from both STAMPEDE and CHAARTED dat...
|
- Details
- At the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019), Charles Ryan is joined by three physicians to discuss disparities and outcomes in men with prostate cancer. Drs. Susan Halabi, Mindy DeRouen, and Dan George shared highlights from their presentations from the PCF Scientific Retreat. Dr. Hebert-DeRouen shares details on the Disparities Research: Environment and multi oMics...
|
- Details
- At the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) Dana Rathkopf and Alicia Morgans discuss the IRONMAN registry. Dana, a strong contributor to the IRONMAN registry trial, explains the goals of the registry and why it is so important for the personalization of patient care around the world. The IRONMAN registry is a population-based observational study currently in nine co...
|
- Details
- Sarah Wise, the Director of Research Operations at the Prostate Cancer Clinical Trials Consortium (PCCTC) sits down with Alicia Morgans to talk about the PCCTC, what the goals of the organization are, the benefit of the organization to patients, and how physicians, clinicians, and researchers can support what they are trying to do. The Prostate Cancer Clinical Trials Consortium (PCCTC) was initiat...
|
- Details
- Robert Reiter and Phillip Koo discuss his lecture on oligometastatic disease at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Dr. Reiter highlights next-generation imaging and its impact on managing patients with oligometastatic disease. Biographies: Robert E. Reiter, MD, MBA, the Bing Professor of Urologic Oncology and Director of UCLA's prostate cancer program, Director of Urol...
|
- Details
- In this conversation with Charles Ryan, Mark Rubin highlights the key points he addresses in his 2019 Advanced Prostate Cancer Consensus Conference presentation where he speaks about the future of biomarkers in advanced prostate cancer. Biographies: Mark A. Rubin, MD, Professor, Principal Investigator, and Director Department for BioMedical Research (DBMR), University of Bern, Switzerland. Dr. Rub...
|
- Details
- William Oh highlights the first study of people who were exposed to the World Trade Center dust and who subsequently developed prostate cancer. World Trade Center responders with prostate cancer showed signs that inflammation was activated in the prostate after exposure to dust from the World Trade Center site, possibly causing chronic inflammation that contributed to their cancer, according to a...
|
- Details
- Charles Ryan and Alicia Morgans encourage participation in a 6 minute (survey) study available on UroToday.com, titled the Global vs. Expert Consensus in the Management of Advanced Prostate Cancer Study , a questionnaire intended to determine the global consensus among all physicians treating patients with advanced prostate cancer. The aim is to further understand global patterns of care in advanc...
|
